Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab or Pembrolizumab With Histology-Specific Chemotherapy for Operable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
Latest Information Update: 24 Mar 2023
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 20 Mar 2023 Planned End Date changed from 1 Mar 2024 to 27 Dec 2025.
- 20 Mar 2023 Planned primary completion date changed from 1 Mar 2023 to 27 Aug 2025.
- 07 May 2021 Planned initiation date changed from 1 Mar 2021 to 1 Jun 2021.